菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Innovative Bispecific Antibody Engineering & Production Platforms

Quick ‘n’ Clean
Unlock Optimal Pairings Quickly & Cost-Effectively

 

The Quick ‘n’ Clean platform uses our high-titer CHO transient expression platform to offer fast and cost-effective identification of optimal bispecific antibody pairings at the early research stage.

 

Key Features: 
  • 99% heterodimer, >95% monomer, <0.5 EU/mg endotoxin
  • Automated 3-step purification including SEC
  • 1-7 mg bispecific antibodies from 20 mL cell culture within 4 weeks
  • Suitable for most in vitro and some in vivo studies

 

Case Study

Premium BsAb
LC-MS-Driven Purification for High-Purity Bispecific Antibodies

 

The Premium Bispecific Antibody (BsAb) platform utilizes LC-MS-assisted purification to remove homodimers, achieving bispecific heterodimers purity of 98% or more and endotoxin levels <0.01 EU/mg.

 

Key Features:

  • LC-MS-driven purification
  • Delivering 3,000 bispecific antibodies with various formats
  • 10 mg to grams of bispecific antibodies in just 4-6 weeks
  • Premium quality (heterodimer purity >98%, endotoxin <0.01 EU/mg)

 

Case Study

WuXiBody™
Novel Bispecific Antibody Format Eliminating Chain Mispairing

 

WuXiBody™ is our proprietary platform designed to eliminate heavy/light chain mispairing and simplify byproduct separation in bispecific antibody production.

 

Key Features:

  • Eliminating heavy/light chain mispairing
  • Assembling any mAb sequence pair into IgG-like structures
  • Flexible formats with different valencies
  • Clinically validated bispecific antibody format

 

Case Study

Discuss Your BsAb Project with the Experts

Contact Us

Quick ‘n’ Clean Case Study
In this case study, we produced Fab-scFv using the Quick ‘n’ Clean platform. Through a 3-step purification process (Ni, Anti-Flag, and SEC), we achieved high titers of 1.2 g/L across 17 Fab-scFv molecules, all with 98.5% purity and endotoxin levels as low as 0.09 EU/mg

Premium BsAb Case Study
This case study highlights our use of Intact Mass to guide bispecific antibody purification. Mixed mode and CEX were employed as purification steps, achieving high-purity heterodimers indicated by Intact Mass.

WuXiBody™ Case Study

This case study demonstrates that WuXiBody™ eliminates LC mispairing and simplifies polishing to a single CEX step, resulting in exceptionally high heterodimer purity.

Your Project. Our Expertise.

Contact Us

Videos

 

Quick ‘n’ Clean: Unlock the Optimal Pairings of Bispecific Antibodies (BsAbs)

 

 

Premium BsAb: LC-MS Assisted Purification for High-Purity Bispecific Antibodies (BsAbs)

Webinars

 

Unlock the Optimal Pairings of Bispecific Antibody Through Small Scale HTP BsAb Production & Efficient Scale-up Strategies

 

In this webinar, you will learn:

  • Novel strategies for optimizing the production of bispecific antibodies in drug development.
  • An innovative high throughput production platform to quickly screen the optimal pairings of bispecific antibody for accelerated discovery.
  • Cutting-edge technologies for large scale production of bispecific antibodies.

 

 

Watch the Webinar On-Demand Now

 

Innovative Production and Engineering Strategies for Fab, ScFv & VHH

 

In this webinar, you will learn:

  • Novel strategies to tackle common production challenges like low yields, throughput issues, and impurities in antibody fragment production.
  • Advanced molecule engineering and linker design to mitigate aggregation and increase yield.
  • Tailored approaches for optimizing the production of Fab, ScFv, and VHH, with a focus on specific strategies for each fragment type.

 

 

Watch the Webinar On-Demand Now

Posters

High-Titer, High-Purity Bispecific
Antibodies Tailored to Your Needs

 

WuXi Biologics provides innovative platforms for bispecific antibody engineering and production, from identifying optimal pairings through high-throughput small-scale production, to overcoming unique challenges across various formats—delivering high-purity, gram-level bsAbs, suitable for in vivo and in vitro studies.

Stay On The Forefront Of Biologics
Discovery & Development

Follow us on LinkedIn